News
Elucid Adds Clinical and Commercial Leadership Ahead of PlaqueIQ™ Launch
BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...
Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule
Decision makes crucial cardiovascular imaging and CT-based technologies more economically viable to hospital outpatient and ambulatory care providers BOSTON – November 4, 2024 – Elucid Bioimaging, Inc. has announced a final rule from US Centers for Medicare &...
Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis
Noridian latest MAC to make Elucid PlaqueIQTM image analysis software available for eligible patients BOSTON – October 25, 2024 – Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared...
Elucid Announces Favorable Medicare Coverage of AI Coronary Plaque Analysis
New policy to make company’s PlaqueIQTM image analysis software available to eligible patients with suspected coronary artery disease BOSTON – October 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend...
Elucid Receives U.S. 510(k) Clearance of PlaqueIQ™ Image Analysis Software to Aid Cardiovascular Disease Assessment
First and Only Software Validated on Ground-Truth Histology, the Gold Standard for Plaque Characterization BOSTON, Oct. 1, 2024 – Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis...
Elucid Names Kelly Huang as CEO
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software BOSTON, July 22, 2024 – Elucid, a pioneering AI medical technology company providing physicians with imaging...
Elucid Commences International PRE-VUE CCT Registry Study
Multi-center, Retrospective Trial to Assess Prognostic Accuracy of Elucid’s Plaque and Plaque-based FFRCT Software in Patients with Clinically Indicated CCTA SCCT2024, WASHINGTON, D.C., and BOSTON, July 18, 2024 – Elucid, a pioneering AI medical technology company...
Elucid Moves into New Headquarters in Preparation for Commercial Launch
Modern Space Allows Room for Growth, Collaboration and Wellness BOSTON, June 27, 2024 -- Elucid, a pioneering medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular disease,...
Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies
Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular risk BOSTON, Nov. 9, 2023 – Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to...
Elucid Appoints Windi Hary to Lead Regulatory Affairs and Quality Management
BOSTON, Sept. 6, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Windi Hary as senior vice president (SVP) of regulatory affairs and quality...
Elucid Names Scott Huennekens Executive Chairman of the Board
BOSTON, April 25, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of...
Andrew Miller Joins Elucid as Chief Technology Officer
BOSTON, March 28, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead...
Elucid Appoints Scott Burger as Chief Commercial Officer
Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago.
Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program
Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago.
Elucid Appoints Dr. Michael Lesh to Board of Directors
Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.